MediWound Ltd. (MDWD)
NASDAQ: MDWD · Real-Time Price · USD
13.59
+0.05 (0.37%)
At close: Nov 20, 2026, 4:00 PM EST
13.62
+0.03 (0.22%)
After-hours: Nov 20, 2026, 7:30 PM EST
MediWound Revenue
MediWound had revenue of $3.57M in the quarter ending September 30, 2026, a decrease of -34.19%. This brings the company's total for the last twelve months to $10.01M, down -52.19% year-over-year. In the year 2025, MediWound had annual revenue of $16.96M, down -16.14%. That makes MediWound the 37,408th largest company in the world by revenue and 4,894th in the United States.
Revenue (ttm)
$10.01M
Revenue Growth
-52.19%
P/S Ratio
19.41
Revenue / Employee
$82,702
Employees
121
Market Cap
194.20M
Revenue by Geography
- USA 11.78M 69.5%
- Rest of The World 2.07M 12.2%
- Spain 1.29M 7.6%
- Italy 1.00M 5.9%
- Germany 817.00K 4.8%
Fiscal year ended Dec 31, 2025 See the full MediWound breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.96M | -3.26M | -16.14% |
| Dec 31, 2024 | 20.22M | 1.54M | 8.22% |
| Dec 31, 2023 | 18.69M | -7.81M | -29.48% |
| Dec 31, 2022 | 26.50M | 2.73M | 11.50% |
| Dec 31, 2021 | 23.76M | 2.00M | 9.19% |
| Dec 31, 2020 | 21.76M | -10.03M | -31.54% |
| Dec 31, 2019 | 31.79M | 28.39M | 834.70% |
| Dec 31, 2018 | 3.40M | 905.00K | 36.26% |
| Dec 31, 2017 | 2.50M | 938.00K | 60.21% |
| Dec 31, 2016 | 1.56M | 957.00K | 159.23% |
| Dec 31, 2015 | 601.00K | 342.00K | 132.05% |
| Dec 31, 2014 | 259.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Bicycle Therapeutics | 83.53M |
| vTv Therapeutics | 36.84M |
| AC Immune | 23.75M |
| Alpha Cognition | 20.20M |
| Lineage Cell Therapeutics | 10.84M |
| Cartesian Therapeutics | 1.03M |
| Artiva Biotherapeutics | 251.00K |
MDWD News
- 5 days ago - MediWound to Host Virtual KOL Event on EscharEx® Phase III VALUE Study and Commercial Opportunity on December 2, 2026 - GlobeNewsWire
- 8 days ago - MediWound price target lowered to $30 from $36 at Craig-Hallum - TheFly
- 9 days ago - MediWound Earnings Call Transcript: Q3 2026 - Transcripts
- 9 days ago - MediWound Earnings release: Q3 2026 - Filings
- 9 days ago - MediWound reports Q3 EPS (65c), consensus (73c) - TheFly
- 9 days ago - MediWound Reports Third Quarter 2026 Financial Results and Provides Corporate Update - GlobeNewsWire
- 9 days ago - MediWound Slides: Company presentation - Filings
- 16 days ago - MediWound Announces Closing of $17.25 Million Bought Deal Offering of Ordinary Shares - GlobeNewsWire